We, the undersigned, are investigators participating in the NIH Health Care Systems Research Collaboratory, which conducts large pragmatic trials conducted in partnership with and embedded in health care systems. Many of the trials conducted in the Collaboratory are comparative effectiveness research that may use FDA regulated drugs and devices. We applaud the proposed rule to allow for a waiver or alteration of informed consent for clinical investigations posing no more than minimal risk to a human participant and including appropriate safeguards.

We agree about the broad benefits described in the proposed rule—healthcare advances, reduction in burden from harmonizing FDA’s regulations with the Common Rule, and reduced burden and costs for the IRB—and articulate some more specific benefits below.

1. The proposed rule may help enable a Learning Health System (LHS) in which clinicians are able to continually learn from data collected at the point of care to improve both individual care and public health (Committee on the Learning Health Care System in America and Institute of Medicine 2013). Waiving consent for minimal risk research allows for more research to be accomplished with less burden in pursuit of the goal of a LHS.

2. We agree with the proposed rule’s statement that it will facilitate the “investigators’ ability to conduct minimal risk clinical investigations that could contribute substantially to the development of products to diagnose or treat diseases or other conditions, without compromising subjects’ rights, safety, or welfare.” By allowing a waiver of consent for minimal risk research, patients can more readily be prospectively randomly assigned to different treatments that are thought to be in clinical equipoise in order to gather evidence on the comparative risks, burdens, and benefits of the interventions in real-world settings.

3. As noted in the proposed rule, FDA regulations requiring informed consent for investigational use of drugs were developed in 1962, and the 21st Century Cures Act of 2016 encourages a more modern consideration of how data can be used in a clinical setting. Taking this one step further, the modern technical sector has been using data to advance knowledge and understanding for decades; and yet, in the clinical realm, the evidence regarding the risks, burdens and benefits of drugs and devices remains inadequate (Tricoci et al. 2009). Consequently, clinicians must base some of their treatment decisions on inferior and imprecise information. Updating rules to ease certain regulations around informed consent will result in more and better data on which to base clinical treatment decisions.

Thank you for the opportunity to comment on the proposed rule.

Sincerely,

Lesley Curtis, PhD
Professor in Population Health Sciences, Professor in Medicine
Duke University School of Medicine
Interim Executive Director, Duke Clinical Research Institute
Chair in the Department of Population Health Sciences

Kevin Weinfurt, PhD
Professor and Vice Chair for Research in the Department of Population Health Sciences
Duke University School of Medicine
Professor of Psychiatry and Behavioral Science
Duke University Medical Center

Adrian Hernandez, MD
Vice Dean for Clinical Research
Duke University School of Medicine

Sheana Bull, PhD, MPH
Professor, Colorado School of Public Health
Assistant Vice Chancellor, Digital Education
Director, MHealth Impact Library

Judith Carrithers, JD, MPA
Director of Regulatory Services
Advarra

Gloria Coronado, PhD
Senior Investigator
Kaiser Permanente Northwest
Center for Health Research Northwest

Lynn DeBar, PhD MPH
Senior Scientist
Kaiser Permanente Washington Health Research Institute

Gail D’Onofrio MD, MS
Professor and Chair
Department of Emergency Medicine
Yale School of Medicine

Laura M. Dember, MD
Professor of Medicine and Epidemiology
Renal, Electrolyte and Hypertension Division
University of Pennsylvania

Erik G. Van Eaton, MD, FACS
Associate Professor
Department of Surgery
Adjunct Associate Professor
Department of Biomedical Informatics and Medical Education
University of Washington

*Beverly Green, MD, MPH*
Senior Investigator and Family Physician
Kaiser Permanente Washington Health Research Institute and Kaiser Permanente Washington

*Corita R. Grudzen, MD, MSHS, FACEP*
Vice Chair for Research
Associate Professor of Emergency Medicine and Population Health
Ronald O. Perelman Department of Emergency Medicine
NYU School of Medicine

*P. Michael Ho, MD, PhD*
Professor, Department of Medicine,
University of Colorado Denver

*Susan Huang, MD*
Professor, Infectious Disease
School of Medicine
Medical Director, Epidemiology and Infection Prevention
University of California Irvine

*Jeffrey G. Jarvik MD MPH*
Professor, Radiology, Neurological Surgery and Health Services
Adjunct Professor, Pharmacy and Orthopedics & Sports Medicine
Co-Director, Comparative Effectiveness, Cost and Outcomes Research Center
Director, UW CLEAR Center for Musculoskeletal Disorders
University of Washington School of Medicine

*Edward R. Melnick, MD, MHS*
Assistant Professor of Emergency Medicine
Program Director, Yale-VA Clinical Informatics Fellowship Program
Yale School of Medicine

*Susan L. Mitchell, MD, MPH*
Senior Scientist, Director of Palliative Care Research, Co-Director of the Interventional Studies in Aging Center, Hinda and Arthur Marcus Institute for Aging Research
Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center

*Vincent Mor, PhD*
Florence Grant Pirce Professor
Department of Health Services, Policy & Practice
Brown University School of Public Health

*Ed Septimus, MD, FIDSA, FACP, FSHEA*
Therapeutics Research and Infectious Disease Epidemiology, Department of Population Medicine
Harvard Medical School & Harvard Pilgrim Health Care Institute
Texas A&M College of Medicine

*Gregory Simon MD, MPH*
Investigator, Kaiser Permanente Washington Health Research Institute
Psychiatrist, Behavioral Health Service
Kaiser Permanente

*Stacy Sterling, DrPH, MSW*
Research Scientist I
Drug and Alcohol Research Team
Behavioral Health Research Initiative
Mental Health Research Network
Kaiser Permanente Division of Research

*Jeremy Sugarman, MD, MPH, MA*
Harvey M. Meyerhoff Professor of Bioethics and Medicine
Berman Institute of Bioethics and School of Medicine
Johns Hopkins University

*Robert Toto, MD*
Associate Dean, Translational Science
Professor
UT Southwestern Medical Center

*James A. Tulsky, MD*
Professor, Medicine, Harvard Medical School
Chair, Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute
Chief, Division of Palliative Medicine, Medicine, Brigham And Women's Hosp

*Miguel Vazquez, M.D.*
Medical Director of Kidney Transplantation
UT Southwestern Medical Center

*Angelo Volandes, MD*
Associate Professor of Medicine
Myles Selig Wolf, MD
Professor of Medicine
Charles Johnson, M.D. Professor of Medicine
Chief of Nephrology
Duke University School of Medicine

Douglas Zatzick, MD
Professor and Associate Vice Chair for Health Services in the Department of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine

References: